Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Geron Corp. (GERN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.95-12.03%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.07 → 0.07 EPS · FY ending Dec 31, 2027 · 4 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 4; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for GERN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Management stability and execution | A supporting condition in Geron Corp.'s published investment case. The stated target is stable leadership and execution progress. | Improving | further key executive departures or failed restructuring | Qualitative: RYTELO rev $220M-$240M vs guidance; no exec departures RYTELO revenue outlook confirmed; Germany launch initiated; no key executive departures reported in recent filings. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a commercial-stage biotech business, with a thesis centered on growing demand for its product rather than established profitability. The long-term thesis is intact, but the overall signal has shifted from mildly favorable to mixed.
The evidence snapshot does not include valuation measures or market expectations, so whether GERN is cheap or expensive versus peers cannot be assessed. It also does not show what growth or profitability expectations are already reflected in the valuation.
In the near term, U.S. RYTELO demand has been growing: second-quarter 2026 net product revenue was higher than a year earlier, and management reported a third consecutive quarter of demand growth. Expense discipline remains mixed, and the company is loss-making; the evidence on expansion outside the U.S. shows stated intent but limited progress detail.
Over the next few quarters, continued RYTELO demand growth and delivery within the 2026 expense guidance are key execution tests. A guidance cut would be a meaningful negative, while stronger results and guidance from healthcare peers could support sector momentum; weakening jobs data could add pressure to cyclical and healthcare names.
For the next 1 to 3 years, the thesis rests on converting U.S. RYTELO demand into sustained growth while controlling expenses and showing progress outside the U.S. Losses and elevated risk remain central, and the evidence does not establish whether the valuation already reflects the growth prospects. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Operating expenses are guided around $230 million, showing cost discipline. |
| Intact |
| operating expenses exceed $240 million in FY26 |
Operating margin: 9.63% FY2026-Q3; GAAP. Published target: >= $230 million and <= $240 million. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 20269.634491 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
RYTELO net product revenue | Geron aims for RYTELO product sales near $230 million in 2026. | Intact | revenue falls below $220 million in FY26 | Product revenue: $57.473M FY2026-Q2; reported segment. Published target: >= $220 million and <= $240 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 5, 202657,473,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.06 → $0.07 · observed estimates
$0.33B → $0.34B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.06 | $333,135,830 | 2 / 6 |
| 2026-07-25 | $0.06 | $333,136,667 | 4 / 5 |
| 2026-07-26 | $0.06 | $342,335,000 | 2 / 5 |
| 2026-07-27 | $0.06 | $342,335,000 | 2 / 5 |
| 2026-07-28 | $0.08 | $341,787,780 | 3 / 4 |
| 2026-07-29 | $0.06 | $342,335,000 | 2 / 5 |
| 2026-07-30 | $0.06 | $342,335,000 | 2 / 5 |
| 2026-07-31 | $0.06 | $342,335,000 | 2 / 5 |
| 2026-08-01 | $0.08 | $341,787,780 | 3 / 4 |
| 2026-08-02 | $0.06 | $342,335,000 | 2 / 5 |
| 2026-08-03 | $0.06 | $342,335,000 | 2 / 5 |
| 2026-08-04 | $0.06 | $342,335,000 | 2 / 5 |
| 2026-08-05 | $0.06 | $342,335,000 | 2 / 5 |
| 2026-08-06 | $0.08 | $341,787,780 | 3 / 4 |
| 2026-08-07 | $0.07 | $341,962,200 | 3 / 4 |
| 2026-08-08 | $0.06 | $342,375,000 | 2 / 5 |
| 2026-08-09 | $0.06 | $342,375,000 | 2 / 5 |
| 2026-08-10 | $0.06 | $342,375,000 | 2 / 5 |
| 2026-08-12 | $0.04 | $341,962,200 | 1 / 5 |
| 2026-08-13 | $0.04 | $341,962,200 | 1 / 5 |
| 2026-08-14 | $0.07 | $341,962,200 | 3 / 4 |
| 2026-08-15 | $0.07 | $341,962,200 | 3 / 4 |
| 2026-08-16 | $0.07 | $341,962,200 | 3 / 4 |
| 2026-08-17 | $0.07 | $341,962,200 | 3 / 4 |
| 2026-08-18 | $0.07 | $341,962,200 | 3 / 4 |
| 2026-08-19 | $0.07 | $341,962,200 | 3 / 4 |
| 2026-08-20 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-08-21 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-08-22 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-08-23 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-08-24 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-08-25 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-08-26 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-08-27 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-08-28 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-08-29 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-08-30 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-08-31 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-01 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-02 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-03 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-04 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-05 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-06 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-07 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-08 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-09 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-10 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-11 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-12 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-13 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-14 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-15 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-16 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-17 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-18 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-19 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-20 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-21 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-22 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-23 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-24 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-25 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-26 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-27 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-28 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-29 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-09-30 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-01 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-02 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-03 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-04 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-05 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-06 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-07 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-08 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-09 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-10 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-11 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-12 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-13 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-14 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-15 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-16 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-17 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-18 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-19 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-20 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-21 | $0.07 | $341,971,800 | 3 / 4 |
| 2026-10-22 | $0.07 | $341,042,200 | 3 / 4 |
| 2026-10-23 | $0.07 | $341,042,200 | 3 / 4 |
| 2026-10-24 | $0.07 | $341,042,200 | 3 / 4 |
| 2026-10-25 | $0.07 | $341,042,200 | 3 / 4 |
| 2026-10-26 | $0.07 | $341,042,200 | 3 / 4 |
| 2026-10-27 | $0.07 | $341,042,200 | 3 / 4 |
| 2026-10-28 | $0.07 | $341,042,200 | 3 / 4 |
| 2026-10-29 | $0.07 | $341,046,400 | 3 / 4 |
| 2026-10-30 | $0.07 | $341,046,400 | 4 / 4 |
| 2026-10-31 | $0.07 | $341,046,400 | 4 / 4 |
| 2026-11-01 | $0.07 | $341,046,400 | 4 / 4 |
| 2026-11-02 | $0.07 | $341,046,400 | 4 / 4 |
| 2026-11-03 | $0.07 | $341,046,400 | 4 / 4 |
| 2026-11-04 | $0.07 | $341,046,400 | 4 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.